Type2 Diabetes Clinical Trial
Official title:
Breath for Better Health Study
NCT number | NCT03210896 |
Other study ID # | RA315217 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 10, 2017 |
Est. completion date | May 8, 2019 |
Verified date | September 2019 |
Source | University Hospitals Coventry and Warwickshire NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breath analysis is becoming of increasing interest to researchers throughout the world for
disease identification and monitoring. It is known that small chemicals dissolved in the
blood can pass through the blood/air barrier within the lungs and be exhaled in normal
breath, with many of these chemicals being potential biomarkers for a broad range of
diseases. These specific biomarkers need to be identified so that gas analysis instruments
and sensors can be designed to detect these chemicals.
The aim of this study is to determine if there are biomarkers in exhaled breath that
correlate with blood glucose concentration. This biomarker can then be used to produce a new
device that will allow diabetic patients to monitor their blood glucose levels in a quick and
non-invasive way. The investigators believe this will lead to a significant improvement in
the quality of life of those suffering from this condition.
In this study breath samples will be collected using three different methods to maximise the
chemical information available from each breath. Breath samples from Type 2 diabetic patients
will be compared with healthy controls. Subgroups will have repeated breath samples after
drinking orange juice or during normal day-to-day activities. This is to measure any changes
in breath chemicals over time. The chemicals detected will be compared with blood tests, to
identify potential breath biomarkers for blood glucose concentration, and to see if factors
such as sex, age, and diet have any effect on the biomarkers detected.
This is a single centre pilot study taking place at University Hospitals Coventry and
Warwickshire NHS Trust, and the analysis of the breath samples will be carried out at the
University of Warwick.
Status | Completed |
Enrollment | 175 |
Est. completion date | May 8, 2019 |
Est. primary completion date | May 8, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosed clinically with type 2 diabetes Exclusion Criteria: - Consumed alcohol less than 48 hours before the start of the study appointment - Consumed food or drink less than 1 hour before the start of the study appointment - Smoked less than 2 hours before the start of the study appointment - Pregnant - Person who has (or had in the last week) a respiratory infection (either bacterial or viral) - Uses recreational drugs - Those who have had surgery/major injury in the last 4 months - Anyone with a different metabolic, liver, cancer or gastro related disease - Anyone who is taking part in an interventional study - Anyone who is unable to provide written consent |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals Coventry & Warwickshire NHS Trust | Coventry | West Midlands |
Lead Sponsor | Collaborator |
---|---|
University Hospitals Coventry and Warwickshire NHS Trust | University of Warwick |
United Kingdom,
Amal H, Leja M, Funka K, Lasina I, Skapars R, Sivins A, Ancans G, Kikuste I, Vanags A, Tolmanis I, Kirsners A, Kupcinskas L, Haick H. Breath testing as potential colorectal cancer screening tool. Int J Cancer. 2016 Jan 1;138(1):229-36. doi: 10.1002/ijc.29701. Epub 2015 Aug 7. — View Citation
Arasaradnam RP, McFarlane M, Daulton E, Skinner J, O'Connell N, Wurie S, Chambers S, Nwokolo C, Bardhan K, Savage R, Covington J. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD). Dig Liver Dis. 2016 Feb;48(2):148-53. doi: 10.1016/j.dld.2015.10.013. Epub 2015 Nov 22. — View Citation
Arasaradnam RP, McFarlane M, Ling K, Wurie S, O'Connell N, Nwokolo CU, Bardhan KD, Skinner J, Savage RS, Covington JA. Breathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: a pilot study. J Breath Res. 2016 Feb 11;10(1):016012. doi: 10.1088/1752-7155/10/1/016012. — View Citation
Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Tietje O, Wong C. Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat. 2006 Sep;99(1):19-21. Epub 2006 Feb 24. — View Citation
Sahota AS, Gowda R, Arasaradnam RP, Daulton E, Savage RS, Skinner JR, Adams E, Ward SA, Covington JA. A simple breath test for tuberculosis using ion mobility: A pilot study. Tuberculosis (Edinb). 2016 Jul;99:143-6. doi: 10.1016/j.tube.2016.05.005. Epub 2016 May 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chemical components in breath samples will be measured using Ion Mobility Spectrometry, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration. | Repeat breath samples will be collected over time to measure changes in chemical components. | Baseline, 5 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours. | |
Primary | Chemical components in breath will be captured into a plastic tubes (Bio-VOC) followed by Electronic Nose analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration. | Repeat breath samples will be collected over time to measure changes in chemical components. | Baseline, 5 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours. | |
Primary | Chemical components in breath will be captured into absorbent tubes followed by GCMS analysis, to determine if there are potential biomarkers in exhaled breath that can be directly correlated with blood glucose concentration. | Repeat breath samples will be collected over time to measure changes in chemical components. | Baseline, 5 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours. | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as age will be recorded to see if they influence the breath chemical composition. | Baseline | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as sex will be recorded to see if they influence the breath chemical composition. | Baseline | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as smoking habits will be recorded to see if they influence the breath chemical composition. | Baseline | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as medication will be recorded to see if they influence the breath chemical composition. | Baseline | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as food intake will be recorded to see if they influence the breath chemical composition. | Baseline | |
Secondary | Demographic and lifestyle data will be recorded to see if they correlate with breath chemical composition. | Confounding factors such as physical activities will be recorded to see if they influence the breath chemical composition. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|